Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab for uncontrolled hypereosinophilic syndrome
2021-005692-39Phase 3Active
- Sponsor
- GSK
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypereosinophilic syndrome (HES) comparing Depemokimab plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Frequency of HES flares during the 52-week study intervention period. Started Apr 2022; status: active.
02
Drugs
depemokimab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on 2021-005692-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005692-39.